Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health is benefiting from clear execution in 3Q26, where revenue of $725.4mm rose 51.3% year over year and adjusted EBITDA of $34.3mm exceeded expectations despite a slight revenue miss. The business is gaining credibility as Performance Suite launches and renewals, including Highmark and Aetna, are tracking ahead of plan, claims runout is favorable versus initial reserves, and Auth Intelligence is already handling about half of manual reviews. With FY26 adjusted EBITDA guidance raised to $130mm-$135mm, a FY27 midpoint of $150mm+ reiterated, $19.2mm of 3Q FCF, and a plan for up to $50mm of debt reduction, the outlook is underpinned by improving margins, cash generation, and de-risked leverage.

Evolent Health is facing a valuation and execution profile that looks fragile, with the bear case based on 8x FY26 EBITDA and a lower 9x FY2028 multiple reflecting limited confidence in sustained upside. The company’s outlook is pressured by slower client signings, the risk of existing clients switching vendors, and a slower-than-expected shift to value-based care, while 2026/2027 revenue of $2.63/$3.28 billion and adjusted EBITDA of $131/$150 million still imply only modest profitability. Additional headwinds include HCIT spending sensitivity to government programs, constrained hospital budgets, pricing competition, and Medicaid-related membership pressure, including a roughly 7% headwind in Technology & Services and exposure to approximately 600,000 members at Humana.